243 related articles for article (PubMed ID: 33946047)
1. Identification of an immune subtype predicting survival risk and immune activity in hepatocellular carcinoma.
Zhao F; Xu N; Yang J; Li B; Shi J; Zheng Y; Xu L
Aging (Albany NY); 2021 May; 13():. PubMed ID: 33946047
[TBL] [Abstract][Full Text] [Related]
2. Characterizing the key genes of COVID-19 that regulate tumor immune microenvironment and prognosis in hepatocellular carcinoma.
Gao S; Zhang L; Wang H
Funct Integr Genomics; 2023 Aug; 23(3):262. PubMed ID: 37540264
[TBL] [Abstract][Full Text] [Related]
3. Cuproptosis-Related Signature Predicts the Prognosis, Tumor Microenvironment, and Drug Sensitivity of Hepatocellular Carcinoma.
Qi X; Guo J; Chen G; Fang C; Hu L; Li J; Zhang C
J Immunol Res; 2022; 2022():3393027. PubMed ID: 36438201
[TBL] [Abstract][Full Text] [Related]
4. Identification of novel lactate metabolism signatures and molecular subtypes for prognosis in hepatocellular carcinoma.
Guan Q; Pan J; Ren N; Qiao C; Wei M; Li Z
Front Cell Dev Biol; 2022; 10():960277. PubMed ID: 36147735
[No Abstract] [Full Text] [Related]
5. A cellular senescence-related classifier based on a tumorigenesis- and immune infiltration-guided strategy can predict prognosis, immunotherapy response, and candidate drugs in hepatocellular carcinoma.
Luo Y; Liu H; Fu H; Ding GS; Teng F
Front Immunol; 2022; 13():974377. PubMed ID: 36458010
[TBL] [Abstract][Full Text] [Related]
6. Prognostic clinical phenotypes associated with tumor stemness in the immune microenvironment of T-cell exhaustion for hepatocellular carcinoma.
Zhang G
Discov Oncol; 2023 Nov; 14(1):203. PubMed ID: 37957420
[TBL] [Abstract][Full Text] [Related]
7. Identification of fatty acid metabolism-related molecular subtype biomarkers and their correlation with immune checkpoints in cutaneous melanoma.
Xu Y; Chen Y; Jiang W; Yin X; Chen D; Chi Y; Wang Y; Zhang J; Zhang Q; Han Y
Front Immunol; 2022; 13():967277. PubMed ID: 36466837
[TBL] [Abstract][Full Text] [Related]
8. Identification of the immune cell infiltration landscape in pancreatic cancer to assist immunotherapy.
Wang Z; Zou W; Wang F; Zhang G; Chen K; Hu M; Liu R
Future Oncol; 2021 Nov; 17(31):4131-4143. PubMed ID: 34346253
[TBL] [Abstract][Full Text] [Related]
9. Immune cell infiltration and immunotherapy in hepatocellular carcinoma.
Jiang Y; Lin L; Lv H; Zhang H; Jiang L; Ma F; Wang Q; Ma X; Yu S
Math Biosci Eng; 2022 May; 19(7):7178-7200. PubMed ID: 35730302
[TBL] [Abstract][Full Text] [Related]
10. Identification and Characterization of an Ageing-Associated 13-lncRNA Signature That Predicts Prognosis and Immunotherapy in Hepatocellular Carcinoma.
Li F; Xue X
J Oncol; 2023; 2023():4615297. PubMed ID: 36844873
[TBL] [Abstract][Full Text] [Related]
11. Comprehensive analysis of cuproptosis-related lncRNAs in immune infiltration and prognosis in hepatocellular carcinoma.
Liu C; Wu S; Lai L; Liu J; Guo Z; Ye Z; Chen X
BMC Bioinformatics; 2023 Jan; 24(1):4. PubMed ID: 36597032
[TBL] [Abstract][Full Text] [Related]
12. Identification of Hypoxia-Related Subtypes, Establishment of Prognostic Models, and Characteristics of Tumor Microenvironment Infiltration in Colon Cancer.
Wang C; Tang Y; Ma H; Wei S; Hu X; Zhao L; Wang G
Front Genet; 2022; 13():919389. PubMed ID: 35783281
[No Abstract] [Full Text] [Related]
13. Signature construction and molecular subtype identification based on cuproptosis-related genes to predict the prognosis and immune activity of patients with hepatocellular carcinoma.
Peng X; Zhu J; Liu S; Luo C; Wu X; Liu Z; Li Y; Yuan R
Front Immunol; 2022; 13():990790. PubMed ID: 36248822
[TBL] [Abstract][Full Text] [Related]
14. A novel immunogenic cell death-related genes signature for predicting prognosis, immune landscape and immunotherapy effect in hepatocellular carcinoma.
Xu G; Jiang Y; Li Y; Ge J; Xu X; Chen D; Wu J
J Cancer Res Clin Oncol; 2023 Dec; 149(18):16261-16277. PubMed ID: 37698679
[TBL] [Abstract][Full Text] [Related]
15. Identification of cuproptosis-related subtypes, cuproptosis-related gene prognostic index in hepatocellular carcinoma.
Ding L; Li W; Tu J; Cao Z; Li J; Cao H; Liang J; Liang Y; Yu Q; Li G
Front Immunol; 2022; 13():989156. PubMed ID: 36177029
[TBL] [Abstract][Full Text] [Related]
16. Immune checkpoints related-LncRNAs can identify different subtypes of lung cancer and predict immunotherapy and prognosis.
Zhang H; Liu M; Du G; Yu B; Ma X; Gui Y; Cao L; Li X; Tan B
J Cancer Res Clin Oncol; 2022 Jul; 148(7):1597-1612. PubMed ID: 35296921
[TBL] [Abstract][Full Text] [Related]
17. Identification of Two Molecular Subtypes of Hepatocellular Carcinoma Based on Dysregulated Immune LncRNAs.
Lin H; Xie Y; Kong Y; Yang L; Li M
Front Mol Biosci; 2021; 8():625858. PubMed ID: 34888348
[TBL] [Abstract][Full Text] [Related]
18. Identification of the Tumor Immune Microenvironment and Therapeutic Biomarkers by a Novel Molecular Subtype Based on Aging-Related Genes in Hepatocellular Carcinoma.
Cai D; Zhao Z; Hu J; Dai X; Zhong G; Gong J; Qi F
Front Surg; 2022; 9():836080. PubMed ID: 35392063
[TBL] [Abstract][Full Text] [Related]
19. Establishment of a Necroptosis-Related Prognostic Signature to Reveal Immune Infiltration and Predict Drug Sensitivity in Hepatocellular Carcinoma.
Ren H; Zheng J; Cheng Q; Yang X; Fu Q
Front Genet; 2022; 13():900713. PubMed ID: 35957699
[No Abstract] [Full Text] [Related]
20. Comprehensive genomic signature of pyroptosis-related genes and relevant characterization in hepatocellular carcinoma.
Wang S; Gao S; Shan L; Qian X; Luan J; Lv X
PeerJ; 2023; 11():e14691. PubMed ID: 36650832
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]